Document Type : Review Article
Authors
College of Remote Sensing & Geophysics, Al-Karkh University of Science, Baghdad, Iraq
Abstract
Breast Cancer (BC) is a special case in which the breast's cells grow out of control. Different types of breast cancer are developed according to which cells in the breast turn into cancer and different parts of the breast can give rise to breast cancer. Many types of treatment are used to treat breast cancer and metal complexes are one of the most crucial treatments for breast cancer. Numerous metal complexes have been shown effective in the treatment of breast cancer as well as many complexes utilized to treat specific forms of the disease. Metal complexes will help medicinal chemists organize, plan, and put innovative methods toward the development of novel medications into practice. This review highlights the causes and treatments of breast cancer and gives many examples of recent research that uses metal complexes as a medication.
Graphical Abstract
)
Keywords
Main Subjects
[1]. Henry NL, Shah PD, Haider I, Freer PE, Jagsi R, Sabel MS. Chapter 88: Cancer of the Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
[2]. Jagsi R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
[3]. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019.
[4]. Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/ Black people 2022. CA Cancer J Clin. 2022; 72: 202-229.
[5]. Adler C, Diekmann M, Schmidtmann M, Beckhaus R, Zeitschrift für Anorg und Allg. Chemie 2017, 643, 732–735.
[6]. Hassan SA, Lateef SM, Majeed IY. Structural, Spectral and Thermal Studies of New Bidentate Schiff Base Ligand Type (NN) Derived from Mebendazol and 2-Aminobenzothaizol and its Metal Complexes and Evaluation of their Biological Activity. Journal of Global Pharma Technology. 2018; 10:307-317.
[7]. Halcovitch NR, Fryzuk MD, Aust. J. Chem. 2016, 69, 555–560.
[8]. Nomura K, Mitsudome T, Igarashi A, Nagai G, Tsutsumi K, Ina T, Omiya T, Takaya H, Yamazoe S, Organometallics 2017, 36, 530–542.
[9]. Hamieh A, Dey R, Nekoueishahraki B, Samantaray MK, Chen Y, Abou-Hamad E, Basset JM, Chem. Commun. 2017, 53, 7068–7071.
[10]. Parker KDJ, Fryzuk MD, Organometallics 2015, 34, 2037–2047.
[11].Hassan SA, Lateef SM. Synthesis, structural, thermal and biological studies for new Schiff base derived from Isoniazid and it's complexes with metal ions. Egyptian Journal of Chemistry. 2021;64(7):3235-43.
[12]. Wan KY, Roelfes F, Lough AJ, Hahn FE, Morris RH, Organometallics 2018, 37, 491–504.
[13]. Mahmoud WH, Deghadi RG, G. G. Mohamed, Appl. Organomet. Chem. 2018, 32, 1–22.
[14]. Ingalls EL, Holtzen GA, Kaminsky W, Michael FE, J. Organomet. Chem. 2017, 832, 9–11.
[15]. Hassan SA, Hassan WF. Structural and Spectral studies of new mixed Ligand complexes for 2-Amino-4-nitrophenol with some Metallic ions and Evaluation their Biological Activities. Research Journal of Pharmacy and Technology. 2022;15(8):3634-40.
[16]. Lionetti D, Day VW, Blakemore JD, Organometallics 2017, 36, 1897– 1905.
[17]. M. B. Lachachi, T. Benabdallah, P. M. Aguiar, M. H. Youcef, A. C. Whit- wood, J. M. Lynam, Dalt. Trans. 2015, 44, 11919–11928.
[18]. Hassan SA. Synthesis and characterization of mixed ligand complexes from curcumin and new schiff base derived from isatin for some metallic ions and evaluation biological activities. Research Journal of Pharmacy and Technology. 2022;15(4):1537-42.
[19]. Long NJ, Angew. Chem. 1995, 107, 904; Angew. Chem. Int. Ed. Engl.1995, 34, 21–38.
[20]. Green MLH, Marder SR, Thompson ME, Bandy JA, Bloor D, Kolinsky PV, Jones RJ, Nature 1987, 330, 360.
[21]. Wang Y, Herron N, Grushin V.V, LeCloux D, Petrov V, Appl. Phys. Lett. 2001, 79, 449–451.
[22]. Us NJ, Alleyne B, Us PA, Mark E, Us PA, 2009.
[23]. Daum RJ, Ann NY Acad Sci 1957, 125, 229–241.
[24]. Bertrand B, Casini A, Dalt. Trans. 2014, 43, 4209–4219.
[25]. Stringer T, Seldon R, Liu N, Warner D.F, Tam C, Cheng LW, Land KM, Smith PJ, K. Chibale, Smith GS, Dalt. Trans. 2017, 9875–9885.
[26]. Salloom HK, Lateef SM, Hassan SA. Structural, Spectral and Thermal Studies of Novel Tridentate Schiff Base Ligand Type (NOO) as Donor Atoms Derived from Nalidixic Acid and 4-Aminoantipyrine and Metal Complexes and Evaluation of their Biological Activity. Journal of Global Pharma Technology. 2020;12(2):26-36.
[27]. Pravin N, Raman N, Inorg. Chem. Commun. 2013, 36, 45–50.
[28]. Berger AH, Pandolfi PP. Chapter 5: Cancer Susceptibility Syndromes. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
[29]. Kalvanagh, P. A., Kalvanagh, Y. A. Breast Reconstruction: Is It a Feasible and Acceptable Method?. Advanced Journal of Chemistry-Section B: Natural Products and Medical Chemistry, 2023; 5(1): 65-74.
[30]. Kalvanagh, P. A., Kalvanagh, Y. A. A New Therapeutic Approach Based on Silymarin in the Treatment of Breast Cancer. Advanced Journal of Chemistry-Section B: Natural Products and Medical Chemistry, 2023; 5(1): 75-85.
[31]. Walsh MF, Cadoo K, Salo-Mullen EE, Dubard-Gault M, Stadler ZK and Offit K. Chapter 13: Genetic Factors – Hereditary Cancer Predisposition Syndromes. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
[32]. Islami F, Goding Sauer A, Miller KD, cases and deaths attributable to potentially
modifiable risk factors in the United States. CA Cancer J Clin. 2018; 68:31-54.
[33]. Esteva FJ and Gutiérrez C. Chapter 64: Nonepithelial Malignancies of the Breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2014.
[34]. Jagsi R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
[35]. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16): 1233-1241. doi:10.1056/NEJMoa022152.
[36]. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11(10): 927-933. doi:10.1016/S1470-2045(10)70207-2.
[37]. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16): 1233-1241. doi:10.1056/NEJMoa022152.
[38]. a) Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430-2442. doi:10.1016/S0140- 6736(16)32454-0. b) Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. doi:10.1016/ S0140-6736(11)61629-2.
[39]. Farah M. Ibrahim and Saifaldeen M. Abdalhadi. “Performance of Schiff Bases Metal Complexes and their Ligand in Biological Activity: A Review” Al-Nahrain Journal of Science, ANJS, Vol.24 (1), March 2021, pp. 1-10.
[40]. P. Köpf-Maier, H. Köpf, E. W. Neuse, Angew. Chem. 1984, 96, 446; Angew. Chem. Int. Ed. Engl. 1984, 23, 456–457.
[41]. H. Tamura, M. Miwa, Chem. Lett. 1997, 26, 1177–1178.
[42]. D. Osella, M. Ferrali, P. Zanello, F. Laschi, M. Fontani, C. Nervi, G. Cavigiolio, Inorganica Chim. Acta 2000, 306, 42–48.
[43]. U. Schatzschneider, N. Metzler-Nolte, Angew. Chemie - Int. Ed. 2006, 45, 1504–1507.
[44]. A. Vessières, C. Corbet, J. M. Heldt, N. Lories, N. Jouy, I. Laïos, G. Leclercq, G. Jaouen, R. A. Toillon, J. Inorg. Biochem. 2010, 104, 503–511.
[45]. Q. Michard, G. Jaouen, A. Vessieres, B. A. Bernard, J. Inorg. Biochem. 2008, 102, 1980–1985.
[46]. Ahmed Gaber , Walaa F. Alsanie, Deo Nandan Kumar, Moamen S. Refat, and Essa M. Saied. “Novel Papaverine Metal Complexes with Potential Anticancer Activities” Molecules 2020, 25, 5447.
[47]. Hassan SA, Lateef SM, Majeed IY. Structural, Spectral and Thermal studies of new bidentate Schiff base ligand type (NO) derived from Mebendazol and 4-Aminoantipyrine and it's metal complexes and evaluation of their biological activity. Research Journal of Pharmacy and Technology. 2020;13(6):3001-3006.
[48]. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983.
)